Influenza virus strain H5N1 clade 1 vaccine - sanofi pasteur

Drug Profile

Influenza virus strain H5N1 clade 1 vaccine - sanofi pasteur

Alternative Names: AF 03; Avian influenza (bird flu) virus vaccine - sanofi pasteur/NIAID; Emerflu; H5N1 influenza vaccine - sanofi pasteur; H5N1 split antigen influenza vaccine Alum adjuvanted - sanofi pasteur; Low-dose H5N1 vaccine - sanofi pasteur; Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) A/Vietnam/1194/2004 (NIBRG-14) - sanofi pasteur; Pandemic influenza vaccine - sanofi pasteur

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi pasteur
  • Developer Sanofi Pasteur
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Influenza A virus H5N1 subtype

Most Recent Events

  • 29 Nov 2017 Sanofi Pasteur's influenza virus strain H5N1 clade 1 vaccine is registered in USA and Australia and will not be sold commercially
  • 20 Mar 2015 The vaccine is approved in USA and Australia for Influenza A virus H5n1 subtype (Prevention)
  • 20 Mar 2015 No recent reports on development identified - Phase-II for Influenza-A virus H5N1 subtype (In children, Prevention) in Thailand (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top